Boehringer Ingelheim research investment

Boehringer Ingelheim research investment
Boehringer Ingelheim research investment

The pharmaceutical Boehringer Ingelheim is extremely committed to innovation both globally and locally. At a global level, the investment in research, development and innovation (R&D&i) has increased by 14.2 percent in 2023 compared to 2022, with 5.8 billion euros. This sum represents 22.5 percent of the group’s net sales.

Furthermore, only in Spain, investment has increased by 36 percentgoing from 46.1 million euros in 2022 to 62.7 million in 2023. This data reflects 11.5 percent of the net sales of the prescription pharmaceutical products segment of the Spanish subsidiary. Medical Writing interview with Martín Plotquin, director of Medicine and R&D at Boehringer Ingelheim Spain, to take stock of this latest exercise

How has this increase in investment in R&D been achieved compared to the previous year?

Globally, this has been made possible by a strong acceleration of our pipeline, with more advanced trials in key research areas progressing as planned. During the last fiscal year, regulators granted five fast-track designations from the US Food and Drug Administration (FDA) and one breakthrough therapy designation from the US FDA, as well as an EMA PRIME acceptance in Europe. We are pioneering innovative treatments in areas of significant unmet patient medical needs.

These data reflect the company’s solid commitment to R&D. But it is not only a global commitment, but at a local level we have stood out in the last year for a considerable increase in clinical development and industrial innovation.

We have two strategic production plants in Spain, which focus on providing international service. From these we export to more than 80 countries. On the one hand, one of our plants focuses on the production of injectables and orals (for the company’s key medications for the treatment of cardio, kidney and metabolic diseases); On the other hand, the second is dedicated to the manufacturing and packaging of our device for respiratory diseases (such as chronic obstructive pulmonary disease, COPD, and asthma).

These centers have had an investment, in the last seven years, of more than 224 million euros. In addition, we reinforce the innovative nature of the Spanish subsidiary, with the planned plans, as we plan to allocate more than 90 million euros from 2024 to 2027 for a new technological production platform. But, above all, one of the most human figures for us and that most honors us is that in the last year alone we have helped improve the health of 61 million patients worldwide and more than one million in Spain.

What role does Boehringer Ingelheim play if we talk about innovation in Spain?

The results indicate that we continue to be at the forefront of innovation, positioning us as a key agent in the Spanish healthcare ecosystem. We are among the top 11 corporations in the prescription and hospital market and we are the number 1 innovative company in the retail market in the human health sector. In animal health we are leaders in horses and 2nd in pigs and companion animals.

We are one of the companies in the sector that invests the most in research and development. Our research strategy in human health focuses on 6 therapeutic areas: cardio, renal and metabolic diseases, respiratory diseases, oncology, immunology, mental health and retinal health. In animal health, we add value through innovation to prevent and treat diseases in animals and this makes us close to the veterinary profession.

From Spain, we have shown our outstanding role as a strategic site for the group at a global level, being the fourth country with the highest number of clinical trials of the corporation and the third with the most trials in Oncology. Thus, during the last year the company has stood out locally for its high research capacity, participating in up to 67 international human health clinical trials, with an investment of more than 13 million euros.

And beyond R&D&i?

Beyond our commitment to R&D&I, we also innovate by creating digital solutions for health care, as well as in our way of operating, as we advocate for the co-creation of health transformation projects together with institutions, managers, scientific societies and patient organizations, among other agents in our health ecosystem.

In the last year, Boehringer has established itself as a pioneering pharmaceutical company, actively participating in the most important innovation forums both nationally and internationally, including the Mobile World Congress, BioSpain, Health Revolution Congress and South Summit among others, as well as with key agreements with the main technological and innovation hubs. These interventions demonstrate the solid commitment of the company’s Spanish headquarters to the global innovation ecosystem for the transformation of healthcare systems.

We are inspired by the work of co-creation and collaboration with all the agents of the system to walk together towards its transformation, thus favoring a future capable of positively impacting present and future generations. Our goal is to improve the lives of patients (human and animal) with unmet medical needs and we do so beyond our pharmaceutical products, also incorporating new technologies that allow us to be at the forefront of health innovation. We are committed to the potential of data and digitalization to improve prevention, diagnosis, evaluation and treatment, with the use of digital therapies, genetic medicine or Artificial Intelligence.

“We are committed to the potential of data and digitalization to improve prevention, diagnosis, evaluation and treatment.”

These new trends in health are already a reality and therefore, it is necessary to prepare together to incorporate them in an equitable, safe, and responsible way. In addition, we have intensified our work to address the challenges linked to pathologies prevalent among the Spanish population, such as chronic kidney disease, heart failure or pulmonary fibrosis, a common condition in a large group of lung diseases known as ILD.

For this reason, we promote programs such as IntERCede (Models of Care for patients with Chronic Kidney Disease), MAIC (Care Models of care for patients with Heart Failure), to improve their approach with a comprehensive view and with a focus on patients, or on in the field of fibrosis, the QualyEPI project to improve the quality of care for patients with diffuse interstitial lung disease (DILD)

What has been the company’s involvement in international clinical trials?

Our mission is to promote innovation, because improving patient health is the company’s reason for being. Therefore, we initiate new lines of research, identify the health challenges of the future and accelerate new scientific discoveries for patients in those areas where we can do the most good.

From Spain, as we have mentioned, we have participated in 67 international human health clinical trials during the last year. Likewise, our commitment to R&D&i is reflected in the total involvement of more than 10,000 patients locally in clinical trials over the last 10 years.

Spain stands out in the group for its participation in early phases of development with up to three out of four trials in phases I and II. In total, 25 phase I trials have been carried out, 37 percent of them in the oncology area; 27 phase II trials, focused on areas such as immunology, central nervous or respiratory system; and 14 phase III, which represents 21 percent of the total. All of this has led to a total of 578 patients participating in these lines of research, spread across 65 health centers throughout the country. Thus, we have counted 224 participations (number of trials for each of the health centers), 26 percent more compared to the previous year. These figures support Spain’s positioning as an innovative country in scientific advances.

What areas have you focused on?

To face the health challenges of the future and continue improving people’s lives, we have investigated 27 medications for different prevalent pathologies in areas such as mental health, diabetic retinopathy, respiratory diseases, dermatological diseases and cardio, renal and metabolic diseases, among others. others.

What news will your future pipeline bring?

If we talk about future research projects, at a global level, the start of 10 new phase II and phase II trials is planned in the next 12-18 months, with the aim of achieving authorization of 25 new treatments in Human Health until 2030. On the part of Animal Health also, in a global perspective, 20 additional launches are expected in the markets until 2026, including product updates, extensions of indications and new products. Without a doubt, we are going to continue investing in R&D&i to help improve the lives of patients with unmet medical needs, so that we can contribute to the health of people, animals and the environment.

Although it may contain statements, data or notes from health institutions or professionals, the information contained in Medical Writing is edited and prepared by journalists. We recommend the reader that any health-related questions be consulted with a healthcare professional.

For Latest Updates Follow us on Google News


NEXT Eleven applications for each position offered in Medicine and nearly eight in Veterinary Medicine